Oncolytics Biotech, Inc.

Contributing Author

Recent Articles by Oncolytics Biotech, Inc.

Nov-11	Oncolytics Biotech Announces Clinical Supply Agreement to Evaluate Pelareorep in Combination with LOQTORZI (toripalimab-tpzi) in Squamous Cell Anal Carcinoma ONCY +7.81% ONCY -9.62% GlobeNewswire
Nov-09	Pelareorep Induces Coordinated Antiviral Immune Responses and Enhanced Antitumor Immunity in Multiple Myeloma Patients ONCY -7.21% GlobeNewswire
Nov-04	Translational Data from Anal Cancer Patients Show Pelareorep Drives HPV-Specific Immune Responses, Supporting its Potential Across HPV-Driven Cancers ONCY +8.92% GlobeNewswire
Oct-27	Oncolytics Biotech Reports Strong Durability and Survival Data in Anal Cancer, Positioning Pelareorep as Potential Backbone Immunotherapy Across HPV-Driven Cancers ONCY GlobeNewswire
Oct-20	Oncolytics Biotech to Present REO 033 Trial in Progress Abstract at ESMO Showcasing Pelareorep's Potential in Colorectal Cancer ONCY GlobeNewswire
Oct-14	Oncolytics Biotech Provides Update on GOBLET Study Clinical Data and Final PanCAN Grant Payment ONCY +9.84% GlobeNewswire
Oct-12	Oncolytics Biotech Secures Patent Protection to Late 2040s and Provides Intellectual Property Portfolio Update ONCY -15.03% GlobeNewswire
Sep-29	Oncolytics Biotech Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy ONCY GlobeNewswire
Sep-28	Oncolytics Biotech Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer Study ONCY GlobeNewswire
Sep-10	Oncolytics Biotech Announces Positive Preclinical Results Combining Pelareorep with a Pan-RAS Inhibitor in Colorectal Cancer ONCY GlobeNewswire
Aug-18	Oncolytics Biotech Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal Cancer ONCY GlobeNewswire
Jul-20	Oncolytics Biotech Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer ONCY GlobeNewswire
Jul-13	Oncolytics Biotech Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial ONCY GlobeNewswire
Jun-16	Oncolytics Biotech Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044 ONCY +11.68% GlobeNewswire
Jun-02	Oncolytics Biotech Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer ONCY -12.49% GlobeNewswire
Jun-01	Oncolytics Biotech Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches ONCY GlobeNewswire
May-22	Oncolytics Biotech to Present Data at ASCO 2026 Reinforcing Pelareorep's Potential Across Gastrointestinal Tumors ONCY GlobeNewswire
May-04	Oncolytics Biotech Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer ONCY +6.61% GlobeNewswire
Apr-27	Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study ONCY -5.95% GlobeNewswire
Apr-06	Oncolytics Biotech Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer ONCY GlobeNewswire
Apr-01	Oncolytics Biotech Completes Domicile Change to the United States ONCY +9.58% GlobeNewswire
Mar-19	Oncolytics Biotech to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026 ONCY GlobeNewswire
Mar-02	Oncolytics Biotech Launches Randomized Colorectal Cancer Study ONCY -9.73% GlobeNewswire
Feb-24	Oncolytics Biotech to Prioritize Registration-Focused Programs in Anal and Colorectal Cancer ONCY +6.60% GlobeNewswire
Feb-04	Oncolytics Biotech Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer ONCY GlobeNewswire
Jan-15	Oncolytics Biotech Announces Results of Special Meeting of Shareholders ONCY -7.33% GlobeNewswire
Jan-14	Oncolytics Biotech Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics ONCY GlobeNewswire
Jan-12	Oncolytics Biotech Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer ONCY GlobeNewswire
Jan-09	Oncolytics Biotech Outlines Strategic Rationale for Proposal to Change Jurisdiction of Incorporation to Nevada ONCY GlobeNewswire

Oncolytics Biotech, Inc.

Recent Articles by Oncolytics Biotech, Inc.

Upgrade your Finviz experience